{平台标识} {固定描述} Canaccord Genuity has increased its price target for Biodesix (NASDAQ: BDSX), citing updated revenue assumptions for the diagnostics company. The adjustment reflects the analyst's revised expectations for near-term financial performance, though no specific target price or rating change was disclosed.
Canaccord Genuity Raises Price Target for Biodesix Amid Improved Revenue Outlook - {财报副标题}
News Analysis
© 2026 Market Analysis. All data is for informational purposes only.